Diphereline

Selected form

Triptorelin

Method of action: Antigonadotropic, Antitumour, Cytostatic, Endocrine Therapy

Treatment option: Infertility, Female Infertility, Precocious Puberty, Prostatectomy, Cancer, Cancer,Prostate, Endometriosis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diphereline

What is Diphereline?

Diphereline is a pharmaceutical formulation containing triptorelin, which is a synthetic decapeptide analogue of the natural gonadotropin-releasing hormone (GnRH). It belongs to a class of medications known as GnRH agonists.

Mechanism of Action

The medication works by modifying the body's endocrine signals. Under normal physiological conditions, the hypothalamus releases GnRH in pulses to stimulate the pituitary gland, which then signals the production of sex hormones such as testosterone in men and estrogen in women.

Diphereline provides a continuous, rather than a pulsed, stimulation of the pituitary gland. Initially, this causes a brief increase in hormone production. However, with sustained administration, the pituitary gland becomes desensitized. This leads to a significant reduction in the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), ultimately resulting in the suppression of testosterone or estrogen to very low levels.

Clinical Applications

Due to its ability to regulate sex hormones, Diphereline is utilized in several different therapeutic areas:

Oncology: It is frequently used in the management of hormone-responsive prostate cancer. By lowering testosterone levels, the medication can slow or stop the growth of cancer cells that rely on this hormone.
Gynecology: It may be used to treat conditions such as endometriosis or uterine fibroids by reducing estrogen levels, which helps alleviate symptoms and reduce the size of lesions or growths.
Reproductive Medicine: In the context of assisted reproductive technologies, it can be used to prevent premature ovulation during controlled ovarian stimulation.
Pediatrics: It is sometimes indicated for the treatment of central precocious puberty, a condition where puberty begins at an abnormally early age.

Composition and Delivery

Diphereline is typically administered as an injection. It is available in various formulations, including immediate-release forms and sustained-release (depot) formulations. The depot versions are designed to release the active ingredient gradually over a period of one, three, or six months, allowing for long-term hormone suppression with infrequent dosing.

Regulatory References

What side effects are possible with Diphereline?

Possible Side Effects and Safety Information

The safety profile of Diphereline (Triptorelin) is characterized by effects resulting from the intended sustained suppression of sex hormones, as documented in official prescribing information.

Officially Documented Adverse Reactions

Adverse reactions are classified by frequency based on clinical data from regulatory documents, such as the EMA Summary of Product Characteristics (SmPC) and FDA Prescribing Information.

Frequency Classification	Examples of Officially Documented Effects
Very Common (≥ 1/10)	Hot flush, Asthenia (physical weakness). In men: Erectile dysfunction, Decreased libido.
Common (≥ 1/100 to < 1/10)	Injection site reactions (pain, redness), Headache, Musculoskeletal pain, Nausea, Hypertension, Depression, and Mood changes.
Uncommon to Rare	Insomnia, Irritability, Gynaecomastia, Anaphylactic reaction, Confusional state.

Clinically Significant Safety Considerations

Regulatory sources highlight specific, serious safety risks associated with Triptorelin, although they are uncommon or rare. These include a reported risk of Pituitary Apoplexy and, in men with prostate cancer, an increased risk of serious Cardiovascular Events (e.g., myocardial infarction, stroke) is noted in labeling.

Time- and Population-Related Safety Patterns

The label specifies that during the first few weeks of treatment, a transient increase in hormone levels may lead to a temporary worsening or flare-up of symptoms (e.g., bone pain, potential urinary tract obstruction). Furthermore, the long-term use of this medication is officially associated with an increased risk of bone loss and subsequent fracture. Population-specific warnings include the contraindication during Pregnancy and the specific reporting of Idiopathic Intracranial Hypertension in pediatric patients.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information regarding overdose with Diphereline (Triptorelin) indicates that experience in humans is limited.

Documented Overdose Profile

Area of Concern	Official Regulatory Statement
Symptom Profile	Overdose symptoms are expected to be an exaggeration or extension of the medicine's known pharmacological effects (hormone suppression).
Occurrence Risk	Because Diphereline is administered via injection by a healthcare professional, the risk of accidental overdose is considered unlikely.
Management	There is no specific antidote available for Diphereline overdose. Management is symptomatic and consists of supportive care to address any clinical signs that may appear.

When to Seek Immediate Medical Help

If an overdose is suspected or has occurred, or if you or the patient experience severe or unexpected symptoms, immediate medical attention is required.

Contact a healthcare professional, emergency medical services, or a national Poison Control center without delay.

Prompt action is necessary for proper assessment and the initiation of supportive measures, which are critical given the lack of a specific neutralizing agent for this Gonadotropin-Releasing Hormone (GnRH) analogue.

Therapeutic Uses of Diphereline

What Diphereline Treats: Main Uses and Benefits

Diphereline (Triptorelin) provides a specialized therapeutic benefit by managing conditions that are highly dependent on sex hormones (estrogen and testosterone). Its primary role is to bring about controlled hormonal suppression, easing the symptom burden in several distinct clinical domains.

This medication is commonly used across conditions presenting with acute or disruptive symptom patterns, particularly where symptoms relate to heightened physiological activity caused by hormones. Clinically, it is applied in managing advanced prostate cancer, symptomatic endometriosis, uterine fibroids, and Central Precocious Puberty (CPP) in children. Within fertility treatment, it is relevant in contexts involving heightened systemic burden to support controlled ovarian stimulation.

When patients experience intense manifestations, this medication provides support that helps ease the overall symptom load. It is often used during phases when symptoms become more noticeable, helping address symptom clusters that may become disruptive.

“This therapy is commonly used to help manage symptoms that create noticeable physiological strain and interfere with daily functioning.”

Quick Fact: Relief for Hormone-Driven Discomfort

Diphereline helps address symptoms related to physical discomfort and systemic imbalance by easing manifestations such as cancer-related bone pain, chronic pelvic pain, and the accelerated physical changes associated with premature puberty. This supports patients during episodes of heightened discomfort during symptomatic periods.

Regulatory References

MedlinePlus overview of Triptorelin

Eligibility and Restrictions for Use

Who can and cannot use Diphereline?

Diphereline (Triptorelin) eligibility is determined by strict regulatory criteria documented in official government labeling.

Absolute Contraindications

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to triptorelin, any other GnRH agonist, or any component of the formulation. It is also contraindicated in women who are pregnant or who are actively breastfeeding (lactating) due to the potential for fetal harm or adverse effects on the infant.

Approved and Restricted Populations

Use is permitted for adult men with advanced prostate cancer and for adult women for specific gynaecological conditions. For Central Precocious Puberty (CPP), the medicine is approved for children aged 2 years and older, but treatment must be discontinued upon reaching specific bone maturation age thresholds (e.g., 12–13 years for girls). The safety and efficacy are not established for children under two years of age.

Conditional Use

Certain pre-existing conditions necessitate careful monitoring rather than absolute prohibition. For men with prostate cancer, this includes patients at risk of spinal cord compression or urinary tract obstruction. Similarly, patients with metabolic risks like diabetes require monitoring during treatment, as defined in the official regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Diphereline (triptorelin) has documented interactions primarily stemming from its hormonal mechanism and the risk of specific adverse effects, requiring careful medical assessment when used alongside certain medications.

Pharmacologic and Pharmacodynamic Interactions

Drugs that Raise Prolactin Levels: Concomitant use with medicinal products that increase prolactin levels should be avoided. This is due to a pharmacologic antagonism where elevated prolactin can reduce the number of GnRH receptors in the pituitary gland, potentially diminishing Diphereline's intended effect.
QT Prolonging Agents: Androgen deprivation therapy with Diphereline may prolong the QT interval on an electrocardiogram. Patients with a history of or risk factors for QT prolongation, or those receiving other medicines that prolong the QT interval, require careful monitoring. These interacting medicines include Class IA (e.g., quinidine, disopyramide) and Class III (e.g., amiodarone, sotalol) antiarrhythmics, as well as certain antipsychotics, methadone, and moxifloxacin. A physician must assess the benefit-risk ratio, considering the potential for Torsade de pointes.
Drugs Affecting Gonadotropin Secretion: Caution and hormonal status supervision are recommended when co-administering Diphereline with other medicinal products known to affect pituitary secretion of gonadotropins.

Procedural Interaction

Anticoagulants: Caution is required when giving the intramuscular injection to patients who are receiving anticoagulants (such as warfarin) due to an increased risk of haematoma formation (bruising/bleeding) at the injection site.

Mechanism of Action

How Diphereline Works: Mechanism of Action

Diphereline ( triptorelin) modulates the central neuroendocrine regulatory system, specifically the hypothalamic-pituitary-gonadal (HPG) axis. The drug acts as a synthetic agonist, binding to Gonadotropin-Releasing Hormone (GnRH) receptors on the gonadotroph cells of the anterior pituitary gland. This binding initially initiates a surge in the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), engaging the early steps of the HPG cascade.

However, the drug's continuous, non-pulsatile presence at the receptors leads to a subsequent and critical phase of receptor down-regulation and functional desensitization of the pituitary cells. This process results in the sustained suppression of LH and FSH synthesis and secretion into the bloodstream. The resulting physiological effect of deep gonadotropin suppression limits the stimulation of the gonads (testes/ovaries), which ultimately leads to a profound reduction in circulating levels of testosterone and estradiol.

Dosage and Administration Information

Diphereline (Triptorelin) is a specialized prolonged-release depot injection that must be administered under the supervision of a physician. The specific dose is selected based on the required dosing frequency, as the available strengths are not additive.

Official Dosing Regimens and Schedule

Dose Strength	Administration Route	Frequency/Schedule
3.75 mg	Intramuscular (IM) injection	Once every 4 weeks (Monthly)
11.25 mg	Intramuscular (IM) injection	Once every 12 weeks (3 Months)
22.5 mg	Intramuscular (IM) injection	Once every 24 weeks (6 Months)

Administration Instructions

The medicine is supplied as a powder and solvent. The powder must be reconstituted only with the sterile water diluent provided in the package. The resulting suspension should be administered immediately after preparation. Administration is limited to the intramuscular route; intravascular injection must be strictly avoided.

Special procedural conditions require the injection site to be varied periodically. For adult female use in certain conditions, the first dose must be given during the first five days of the menstrual cycle. For pediatric use in Central Precocious Puberty, the approved regimen is typically 22.5 mg every six months.

If a scheduled injection is missed, the patient must immediately contact the prescribing healthcare provider for instructions to maintain the treatment schedule. No dose adjustment is specified for patients with renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diphereline

Evidence for Use in Advanced Prostate Cancer

Research has evaluated Diphereline's use in men with advanced prostate cancer through large clinical trials and meta-analyses. Studies examined whether the treatment was associated with measurements of specific low levels of testosterone (hormonal castration) and tracked the levels of the biomarker PSA (Prostate-Specific Antigen). Findings describe patterns observed in the studies where serum testosterone levels that correspond to the castration threshold were observed in most patient cohorts. These studies contribute to the body of evidence regarding the association between treatment and these key biomarkers.

Evidence for Use in Endometriosis and CPP

For Endometriosis, short-term Randomized Controlled Trials (RCTs) monitored outcomes related to physical discomfort, such as changes in patient-reported pain scores, and examined physical outcomes like lesion size. Some trials reported a pattern of reduced pain scores during the study period. For Central Precocious Puberty (CPP), long-term observational studies explored hormone suppression (LH/FSH) and physical measures like the rate of skeletal maturation. Findings describe patterns observed in the studies where hormone levels corresponding to the prepubertal range were measured.

What is Still Uncertain About Diphereline Research

Evidence is limited in several key areas. Long-term effects are not fully established regarding the duration of symptom relief or recurrence after the treatment period ends for non-oncology conditions. Data for certain groups remain insufficient, as research in special populations (e.g., those with comorbidities) was often smaller in size. Comparative evidence is lacking in some indications against newer or alternative therapies. Research explores short-term changes, but certainty remains low in areas where comparative or long-term data are scarce.

Key Studies & References

A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis

Frequently Asked Questions (FAQ)

Common questions about Diphereline (FAQ)

Q: Can Diphereline be given subcutaneously?

Official regulatory documents specify that Diphereline depot formulations are approved and intended for deep intramuscular (IM) injection only. Regulatory information indicates this route is necessary for its design and approved use, and it is not intended to be given subcutaneously.

Q: How is Diphereline administered?

According to the official product information, Diphereline is supplied as a powder that must be mixed with the provided sterile water diluent. The resulting suspension should be used immediately after mixing and is intended to be administered as a deep intramuscular injection by a healthcare professional.

Q: What are the risks of long-term use of Diphereline?

Official prescribing information notes that long-term use is associated with a reported increased risk of bone loss and subsequent fracture. The labeling also highlights that patients may require monitoring for risks related to serious cardiovascular events and metabolic changes like hyperglycemia (high blood sugar), which are sometimes associated with GnRH agonists.

Q: What is the approved dose for Endometriosis?

Official prescribing information indicates that for the treatment of endometriosis, the approved dosing regimen is typically 3.75 mg, given as a single intramuscular injection every four weeks (monthly). In official prescribing information, the treatment duration is typically limited to a total of six months.

Q: Can I store the mixed injection suspension for later?

The official regulatory instructions state that the suspension for injection should be used immediately after preparation. Because the product is not formulated for storage, any reconstituted product that is not administered right away must be properly discarded.

Q: How soon does Diphereline start to work?

Studies and official information indicate that the start of treatment involves a transient increase in certain hormone levels during the first few weeks after the initial injection. This initial 'flare-up' can sometimes lead to a temporary worsening of symptoms before the sustained phase of hormone suppression begins.

Q: Can I drink alcohol while I am being treated with Diphereline?

The official regulatory label does not document a direct interaction between triptorelin and alcohol. However, alcohol consumption may be a risk factor for certain conditions (like bone loss) that require caution during treatment with this medicine. The official product information advises consulting with a healthcare provider regarding lifestyle factors and co-existing conditions.

Q: What should I do if I am traveling and my injection is due?

Given that Diphereline is a depot injection that relies on strict scheduling for continued efficacy, patients are advised in the product information to contact their healthcare provider or clinic immediately if their injection is due near or during travel. This ensures that the treatment schedule can be maintained.

Q: How long does Diphereline stay in my system after the last dose?

The hormonal effect of Diphereline is sustained for the duration of its approved administration period (1, 3, or 6 months), as it is a depot formulation. The drug's elimination phase may be influenced by the specific dose received and individual patient factors.

Q: Why is the injection site varied periodically?

The official product instructions specify that the injection site should be alternated periodically when the medicine is given. Alternating the injection site is a standard procedural step for intramuscular injections that is typically recommended to help minimize the risk of local reactions or discomfort at the site.

How should Diphereline be stored and disposed of?

How to Store and Dispose of Diphereline?

The official guidelines for Diphereline (Triptorelin) define specific storage conditions and disposal procedures to maintain product integrity and safety.

Storage and Handling Requirement	Official Regulatory Statement
Temperature & Protection	Store the product below 25 C and do not freeze it. Keep the medicine in its original container and outer carton to protect it from light and moisture (EMA, FDA).
In-Use Stability	The suspension for injection must be used immediately after preparation. Any unused, reconstituted product must be discarded (EMA, FDA).
Child Safety	The medicine must be kept out of the sight and reach of children and pets (NPS MedicineWise).
Disposal	Unused medicine, expired doses, and contaminated sharps (needles/syringes) must be disposed of in accordance with local regulatory requirements. Sharps must be placed in a designated puncture-proof container (FDA, EMA).